Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07429500
Starting soon Not applicable

tDCS and Symptom Provocation in Treatment-Resistant OCD

NCT07429500 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Henri Laborit
Phase
Not applicable
Started
2026-04-01
Last updated
2026-02-24

Condition(s) studied

Obsessive - Compulsive Disorder

Investigational drug(s) / intervention(s)

tDCS sessionsymptom provocation

tDCS session: An active bifocal tDCS delivered through a CE-certified stimulator. The bifocal montage consists of an anodal electrode over the right orbitofrontal cortex (OFC) and a cathodal electrode over the supplementary motor area (SMA), with 5X5 cm electrod. Stimulation intensity is set at 2 mA, with a 30-minute session duration, including 30-second ramp-up and ramp-down periods.

symptom provocation: A 3-5 minutes personalised symptom provocation procedure immediately before stimulation. This standardised clinical procedure induces brief activation of obsession-related distress without engaging in compulsions. It is delivered by a trained clinician health-care professional and does not constitute psychotherapeutic treatment.

Study summary

The goal of this clinical trial is to learn if symptom provocation before transcranial Direct Current Stimulation (tDCS) in Obsessive-Compulsive Disorder (OCD) patients. The main question it aims to answer is:

Can symptom-provocation before tDCS improve therapeutic response in OCD patients ?

Researchers will compare the clinical outcomes of OCD patients having received, in one arm, tDCS and, in the other arm, patients having received tDCS preceded by symptom provocation to see if therapeutic response and various other clinical variables differ.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Obsessive-Compulsive Disorder (OCD) according to DSM-5, with a duration ≥ 2 years. * Good insight, defined as a BABS score ≤ 18. * Chronic OCD, with either a Y-BOCS total score \> 20 or a subscale score \> 15. * Treatment-resistant OCD, defined as: * failure of ≥ two adequate trials of SSRIs, or * failure of one SSRI plus augmentation with an atypical antipsychotic, * and/or insufficient response after ≥ one year of cognitive-behavioural therapy. * Stable pharmacological treatment (fixed antidepressant dose) for at least 12 weeks prior to inclusion, with no significant improvement during this period. * Age 18 to 70 years. * Ability to provide informed written consent. * Affiliation with the French social security system. Exclusion Criteria: * Women of childbearing potential without effective contraception, or those unwilling to maintain abstinence or contraception. * Pregnancy or breastfeeding. * Compulsory psychiatric hospitalisation. * Legal guardianship or curatorship. * Current DSM-5 Axis I disorder other than OCD (schizophrenia spectrum, bipolar disorder, substance use). * Current major depressive episode (MADRS \> 21). * Suicide risk (MADRS item 10 \> 3). * Dermatological lesions at electrode placement sites. * History of traumatic brain injury. * Presence of intracranial metal, pacemaker, or epilepsy. * Emergency situations or inability to provide informed consent.

Primary outcome measure(s)

  • Variation of Yale-Brown Obsessive-Compulsive Scale score — measured at baseline and 42 days after the start of the therapy
    The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) is a clinician-administered assessment used to measure the severity of obsessive-compulsive disorder (OCD). Scores range from 0 to 40, with higher scores indicating more severe symptoms.

Trial sites (6)

FacilityCityRegionStatus
CH Camille Claudel Angoulême France
CH Esquirol Limoges France
CHU de Nantes Nantes France
Unité de Recherche Clinique, Centre Hospitalier Henri Laborit Poitiers France
CH Guillaume Régnier Rennes France
CHNDS Thouars France

More Centre Hospitalier Henri Laborit trials in France

French Observatory of ElectroConvulsive Therapy (ECT) Recruiting
Interest of the Tool: Evaluation of Specific Care in an Ecological Environment for Patients Suffering From Schizophrenia-like Disorders Recruiting
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder Recruiting
Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition Recruiting
Influence of Control Deprivation on the Use of the Analytical Cognitive Style in Anorexic Subjects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07429500 on ClinicalTrials.gov ↗ ← All trials in France